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Abstract
Brain tumors are the most common solid tumors of childhood, and the genetic drivers and optimal therapeutic strategies for 
many of the different subtypes remain unknown. Here, we identify that bithalamic gliomas harbor frequent mutations in the 
EGFR oncogene, only rare histone H3 mutation (in contrast to their unilateral counterparts), and a distinct genome-wide 
DNA methylation profile compared to all other glioma subtypes studied to date. These EGFR mutations are either small 
in-frame insertions within exon 20 (intracellular tyrosine kinase domain) or missense mutations within exon 7 (extracellular 
ligand-binding domain) that occur in the absence of accompanying gene amplification. We find these EGFR mutations are 
oncogenic in primary astrocyte models and confer sensitivity to specific tyrosine kinase inhibitors dependent on location 
within the kinase domain or extracellular domain. We initiated treatment with targeted kinase inhibitors in four children 
whose tumors harbor EGFR mutations with encouraging results. This study identifies a promising genomically-tailored 
therapeutic strategy for bithalamic gliomas, a lethal and genetically distinct brain tumor of childhood.
Keywords Bithalamic glioma · Diffuse midline glioma · EGFR · Histone H3 · Pediatric cancer · Molecular 
neuropathology · Tyrosine kinase inhibitor · Afatinib · Osimertinib · Erlotinib · Trametinib
Introduction
Central nervous system (CNS) tumors are the most com-
mon solid tumors of childhood and are the leading cause of 
cancer mortality in children 0–14 years of age [23]. Lethal 
high-grade brain tumors of childhood include medulloblas-
toma, atypical teratoid/rhabdoid tumor, ependymoma, and 
diffuse gliomas. The genetic drivers and optimal therapeutic 
strategy for many of the different subtypes of pediatric CNS 
tumors remain unknown.
Diffuse gliomas are malignant tumors of the CNS that 
cannot be cured by resection alone due to their infiltrative 
growth. Genomic studies over the past 2 decades have identi-
fied that there are several different molecular subtypes of dif-
fuse gliomas that differ according to anatomic location (e.g., 
cerebral hemispheres versus midline structures), patient age 
(e.g., pediatric versus adult), and cell lineage (e.g., astrocytic 
versus oligodendroglial). For example, glioblastomas in the 
cerebral hemispheres of older adults are characterized by fre-
quent TERT promoter mutation, EGFR amplification with 
accompanying mutation or rearrangement, PTEN inactivation, 
and CDKN2A homozygous deletion [5, 16, 41]. In contrast, 
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diffuse lower-grade gliomas in the cerebral hemispheres of 
young adults are characterized by IDH1 or IDH2 mutation, 
with accompanying TP53 and ATRX mutations in astrocytic 
tumors versus accompanying TERT promoter, CIC, and 
FUBP1 mutations in oligodendroglial tumors [8]. Unlike dif-
fuse gliomas within the cerebral hemispheres, diffuse gliomas 
arising within midline structures of the CNS (e.g., thalamus, 
brainstem, and spinal cord) are characterized by a recurrent 
lysine to methionine mutation at codon 27 (p.K27M) in the 
H3F3A or HIST1H3B genes that encode the histone H3 vari-
ants H3.3 and H3.1, respectively [18, 36, 42, 43]. The genetic 
differences in the diffuse glioma subtypes reflect distinct cells 
of origin and underlying molecular pathogenesis, which cor-
relate with distinct clinical outcomes [10].
A unique and poorly characterized subtype of diffuse 
glioma involves the bilateral thalami at time of initial pres-
entation, principally affecting young children. These bitha-
lamic diffuse gliomas are not amenable to surgical resec-
tion, and have a uniformly poor outcome despite radiation 
and conventional cytotoxic chemotherapy [4, 6, 11, 13, 15, 
20, 22, 25, 28, 30, 31, 35, 38, 45]. Though diffuse midline 
gliomas with unilateral thalamic involvement frequently 
harbor histone H3 K27M mutation, bithalamic gliomas in 
children often lack this defining mutation [6]. Genome-wide 
DNA methylation profiling has also revealed that bithalamic 
gliomas have a distinct epigenome compared to their unilat-
eral counterparts [6]. As such, a better understanding of the 
molecular pathogenesis of bithalamic gliomas is needed to 
enable the implementation of new effective targeted thera-
pies for affected children.
Herein, we performed comprehensive genomic and epig-
enomic analysis on a cohort of children with bithalamic glio-
mas. We identified that these tumors harbor frequent muta-
tions in the EGFR oncogene in the absence of accompanying 
gene amplification, most frequently small in-frame inser-
tions within exon 20 encoding the tyrosine kinase domain. 
We assessed therapeutic efficacy of a panel of EGFR kinase 
inhibitors in isogenic primary astrocyte models carrying 
EGFR mutations within the kinase domain or extracellular 
domain. We also initiated treatment with targeted kinase 
inhibitors in four children whose tumors harbor EGFR muta-
tions with encouraging results to date. This study provides 
the foundation for a precision medicine treatment approach 
to bithalamic gliomas, a lethal and genetically distinct brain 
tumor of childhood.
Methods
Study population and tumor specimens
This study was approved by the Committee on Human 
Research of the University of California, San Francisco, 
with a waiver of patient consent. Stereotactic biopsies and 
genomic testing for seven of the children with bithalamic gli-
omas were performed as part of standard prospective clinical 
management for pediatric neuro-oncology patients at UCSF 
Medical Center, whereas genomic testing was performed 
on a retrospective research basis for six children. Four of 
these retrospective patients [annotated in Supplementary 
Table 1 (Online Supplement 1)] were previously reported in 
part, including histone H3 K27M mutation status and DNA 
methylation profiling [6]. Imaging features of the thirteen 
patients were reviewed by an expert neuroradiologist (JVM). 
Pathologic review of all tumor samples was performed by 
two expert neuropathologists (AP and DAS).
Immunohistochemistry
Immunohistochemistry was performed on whole formalin-
fixed, paraffin-embedded tissue sections using the follow-
ing antibodies: histone H3 K27M-mutant protein (RevMAb 
Biosciences, cat # 31-1175-00, rabbit monoclonal clone 
RM192, 1:600 dilution), histone H3 lysine 27 trimethyl-
ated protein (Cell Signaling, cat #9733, rabbit monoclonal 
clone C36B11, 1:50 dilution), and EGFR (Ventana, cat # 
790-4347, rabbit monoclonal clone 5B7, undiluted). Immu-
nostaining for histone H3 K27M-mutant protein and EGFR 
protein was performed in a Ventana BenchMark Ultra auto-
mated stainer using CC1 antigen retrieval. Immunostaining 
for histone H3 lysine 27 trimethylated protein was performed 
in a Leica Bond-Max automated stainer using ER2 antigen 
retrieval. Diaminobenzidine was used as the chromogen, fol-
lowed by hematoxylin counterstain. Histone H3 lysine 27 
trimethylation (H3K27me3) was scored as either intact, lost 
in a subset of the tumor cells (< 75%), lost in the majority of 
tumor cells (> 75%), or lost in all tumor cells (100%).
Targeted next‑generation DNA sequencing 
and mutational analysis
Genomic DNA was extracted from formalin-fixed, paraffin-
embedded blocks of tumor tissue from seven children with 
bithalamic diffuse gliomas using the QIAamp DNA FFPE 
Tissue Kit (Qiagen). Genomic DNA was also extracted from 
a peripheral blood sample for patient #10 using the QIAamp 
DNA Blood Midi Kit (Qiagen). Capture-based next-gener-
ation DNA sequencing was performed using an assay that 
targets all coding exons of 479 cancer-related genes, select 
introns and upstream regulatory regions of 47 genes to ena-
ble detection of structural variants including gene fusions, 
and DNA segments at regular intervals along each chro-
mosome to enable genome-wide copy-number and zygo-
sity analysis, with a total sequencing footprint of 2.8 Mb 
[UCSF500 Cancer Panel; Supplementary Table 2 (Online 
Supplement 1); Ref. [17]). Multiplex library preparation 
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was performed using the KAPA Hyper Prep Kit (Roche) 
according to the manufacturer’s specifications using 250 ng 
of sample DNA. Hybrid capture of pooled libraries was per-
formed using a custom oligonucleotide library (Nimblegen 
SeqCap EZ Choice). Captured libraries were sequenced as 
paired-end 100 bp reads on an Illumina HiSeq 2500 instru-
ment. Sequence reads were mapped to the reference human 
genome build GRCh37 (hg19) using the Burrows–Wheeler 
aligner (BWA). Recalibration and deduplication of reads 
were performed using the Genome Analysis Toolkit 
(GATK). Coverage and sequencing statistics [Supplemen-
tary Table 3 (Online Supplement 1)] were determined using 
Picard CalculateHsMetrics and Picard CollectInsertSizeM-
etrics. While the mean on-target sequencing depth was high 
for most samples (> 300x), three samples (patients #2, #4, 
and #9) had low mean on-target sequencing depth (between 
17 and 26x) due to limited tumor tissue quantity that may 
have limited the sensitivity of detection for genetic altera-
tions. Single-nucleotide variant and insertion/deletion muta-
tion calling were performed with FreeBayes and PinDel. 
Structural variant calling was performed with Delly. Variant 
annotation was performed with Annovar. Single-nucleotide 
variants, insertions/deletions, and structural variants were 
visualized and verified using Integrative Genome Viewer. 
Genome-wide copy-number analysis based on on-target and 
off-target reads was performed by CNVkit and visualized 
using Nexus Copy Number (Biodiscovery).
EGFR exon 20 Sanger sequencing
PCR amplification of exon 20 of the EGFR gene was per-
formed on genomic DNA from the bithalamic glioma of 
patient #7, as well as medulloblastoma from an unrelated 
patient, using the MyFi DNA Polymerase Kit (Bioline). PCR 
products were treated with ExoSAP (Affymetrix) and then 
sequenced using BigDye terminator chemistry (Applied Bio-
systems) following standard techniques. Primer sequences 
used for amplification and sequencing of EGFR exon 20 
were as follows:
EGFR ex20 Fwd: 5′-CAT GCG TCT TCA CCT GGA A-3′.
EGFR ex20 Rev: 5′-CTG CGT GAT GAG CTG CAC -3′.
Genome‑wide DNA methylation profiling
Genomic DNA from ten of the bithalamic gliomas was 
bisulfite converted using the EZ DNA Methylation kit fol-
lowing the manufacturer’s recommended protocol (Zymo 
Research). Bisulfite converted DNA was then amplified, 
fragmented, and hybridized to Infinium EPIC 850k Human 
DNA Methylation BeadChips or Infinium 450k Human 
DNA Methylation BeadChips following the manufactur-
er’s recommended protocol (Illumina). The approximately 
450,000 overlapping CpG sites between the 850k and 450k 
BeadChips were used in the analysis. Methylation data were 
preprocessed using the minfi package (v.1.28.4) in R Bio-
conductor (version 3.5.3) [3]. The detection p value for each 
sample was computed. All samples had detection p values 
less than 0.002. Additional quality control was performed 
by calculating the median log (base2) intensities for methyl-
ated and unmethylated signals for each array. All samples 
had unmethylated and methylated median intensity values 
above 10 that were used for analysis. Beta density plots for 
all samples before and after normalization were also exam-
ined. Functional normalization with NOOB background 
correction and dye-bias normalization was performed [12, 
39]. Probe filtering was performed after normalization. Spe-
cifically, probes located on sex chromosomes, containing 
nucleotide polymorphisms (dbSNP132 Common) within 
five base pairs of and including the targeted CpG site, or 
mapping to multiple sites on hg19 (allowing for one mis-
match), as well as cross reactive probes were removed from 
analysis. Unsupervised analysis of methylation data from 
our cohort of 10 pediatric bithalamic gliomas alongside 616 
glioma reference samples from GSE90496 [Supplementary 
Table 9 (Online Supplement 1)] or 2,801 reference sam-
ples spanning 82 CNS tumor entities and 9 control tissues 
from GSE90496 [Supplementary Table 8 (Online Supple-
ment 1)] was performed using hierarchical clustering and 
t-distributed stochastic neighbor embedding (t-SNE) using 
Rtsne (v.0.15). For the t-SNE plots shown in Fig. 3 and Sup-
plementary Fig. 7 (Online Supplement 2), the 32,000 most 
variably methylated CpG probes, as measured by the stand-
ard deviation of the probe-level beta values across samples, 
were selected for analysis. For the hierarchical clustering 
plot shown in Supplementary Fig. 8 (Online Supplement 2), 
the 5000 most variably methylated CpG probes was selected 
for analysis. Pearson correlation was calculated as the dis-
tance measured between samples.
EGFR cDNA expression vector construction 
and site‑directed mutagenesis
The pBabe-EGFR human wild-type cDNA expression vec-
tor was obtained from Addgene (plasmid #11011). p.A289T 
(exon 7, extracellular domain) and p.A767delinsASVG 
(exon 20, intracellular kinase domain) mutations were 
engineered into the pBabe-EGFR construct by site-directed 
mutagenesis using the QuikChange II XL kit (Stratagene) 
as directed by the manufacturer. The entire coding sequence 
of all expression vectors was verified by Sanger sequencing. 
Primer sequences used for the mutagenesis reactions were 
as follows:
A289T Fwd: 5′-CAA ATA CAG CTT TGGT ACCA CCT 
GCG TGA AGAAG-3’.
A289T Rev: 5′-CTT CTT CAC GCA GGTGG TACC AAA 
GCT GTA TTTG-3’.
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A767delinsASVG Fwd 5′-CGA TGA AGC CTA CGT GAT 
GGC CAG CGT GGG CAG CGT GGA CAA CCC CCA CG-3’.
A767delinsASVG Rev: 5′-CGT GGG GGT TGT CCA CGC 
TGCCC ACG CTG GCC ATC ACG TAG GCT TCA TCG-3’.
Immortalized human astrocytes and cell culture
SVG-p12 immortalized human fetal astrocytes were 
obtained directly from ATCC. Normal human astrocytes 
immortalized by retroviral transduction of hTERT, E6, and 
E7 proteins were generously provided by Dr. Russ Pieper 
(University of California, San Francisco). Immortalized 
human astrocyte cultures were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10% 
fetal bovine serum at 37 °C in 5%  CO2.
Lentiviral production and infection
Empty pBabe vector or pBabe-EGFR wild-type and mutant 
expression vectors were co-transfected into 293 T cells with 
pVSV-G and pHR-CMV8.2deltaR helper plasmids using 
Fugene 6 (Roche) as described by the manufacturer. Virus-
containing conditioned medium was harvested 48 h after 
transfection, filtered, and used to infect recipient cells in the 
presence of 5 ug/mL polybrene.
Western blot
Primary antibodies used were EGFR (Cell Signaling, cat 
#4267, clone D38B1, 1:500 dilution), phospho-p44/42 ERK 
Thr202/Tyr204 (Cell Signaling, cat #4370, clone D13.14.4E, 
1:250 dilution), phospho-Akt Ser473 (Cell Signaling, cat 
#4060, clone D9E, 1:250 dilution), and β-actin (Sigma, cat# 
A5441, clone AC-15, 1:5,000 dilution). Total cell lysates 
were extracted from immortalized human astrocytes in RIPA 
buffer containing protease and phosphatase inhibitor cocktail 
(Pierce, cat# 88668), resolved by SDS-PAGE, and immuno-
blotted following standard biochemical techniques.
Soft agar colony forming assay
EGFR wild-type and mutant expressing lentivirus was 
added to exponentially growing immortalized human astro-
cytes in the presence of 5 ug/mL polybrene. At 24 h follow-
ing infection, 20,000 cells were suspended in 0.3% agar in 
DMEM + 10% fetal bovine serum and cast onto a bottom 
layer of 0.6% agar in DMEM + 10% fetal bovine serum in 
6-well tissue culture plates. Soft agar plates were incubated 
in a humidified chamber at 37 °C containing 5%  CO2 for 
21 days. Colonies were imaged and counted on a GelCount 
Colony Counter (Oxford Optronix). Twelve replicates from 
two independent experiments were performed for each 
experimental condition.
Kinase inhibitor sensitivity assay
The CellTiter-Glo assay (Promega) was used to assess cell 
survival following treatment with a panel of small-molecule 
kinase inhibitors on two immortalized human astrocyte cell 
lines. Following lentiviral transduction with empty vector, 
wild-type EGFR, or mutant EGFR isoforms, 200 exponen-
tially growing cells were seeded per well in clear-bottom 
white polystyrene 96-well microplates (Corning 3903). At 
24 h after seeding, cells were treated with DMSO vehicle or 
the small-molecule kinase inhibitors at the indicated con-
centrations. At 4 days following treatment, an equal volume 
of CellTiter-Glo One Solution reagent was added to each of 
the wells, followed by shaking for 5 min at 120 rpm at room 
temperature. Luminescence was measured using the Spec-
traMax M5 spectrophotometer (Molecular Devices). All 
drugs were obtained from Selleck Chemicals and dissolved 
in DMSO. The following agents were used: erlotinib (cat 
# S1023), gefitinib (cat # S1025), lapatinib (cat # S2111), 
poziotinib (cat # S7358), afatinib (cat # S1011), osimertinib 
(cat # S7297), neratinib (cat # S2150), and trametinib (cat # 
S2673). 9 replicates from 3 independent experiments were 
performed for each experimental condition in the SVG-p12 
cells, and 6 replicates from 2 independent experiments were 
performed for each experimental condition in the iNHA 
cells. Percent survival was assessed as the mean lumines-
cence of the experimental condition relative to the mean 
luminescence of the cells treated with DMSO vehicle.
Quantification and statistical analysis
Statistical analysis was performed using GraphPad Prism. 
All error bars shown in colony forming assay and kinase 
inhibitor sensitivity assay plots represent standard error of 
the mean. The Kaplan–Meier survival analysis shown in 
Fig. 5b, c includes 41 children with bithalamic gliomas, 
comprised of the 13 patients from this study combined with 
all historical cases of biopsy-proven bithalamic diffuse glio-
mas in children reported in the literature [see collated clini-
cal data in Supplementary Table 11 (Online Supplement 1)]. 
This survival analysis encompasses all reported cases that 
could be identified of diffuse gliomas of the bilateral thalami 
in children with histology reported as diffuse astrocytoma, 
anaplastic astrocytoma, or glioblastoma (excludes pilocytic 
astrocytoma and astrocytomas with KIAA1549-BRAF fusion, 
as these do not represent true bithalamic diffuse gliomas). 
The Kaplan–Meier survival analysis shown in Fig. 5d is 
limited to the 11 children from this study cohort with bitha-
lamic gliomas harboring EGFR mutations and is stratified 
by those whose therapy included a small-molecule EGFR or 
MEK kinase inhibitor versus those children whose treatment 
did not include a small-molecule tyrosine kinase inhibitor. p 
value was calculated by log-rank (Mantel–Cox) test.
Acta Neuropathologica 
1 3
Availability of data and material
Targeted DNA sequencing data from this study are avail-
able from the European Genome-Phenome Archive (EGA) 
repository under accession number EGAS00001004033 
(https ://ega-archi ve.org/). DNA methylation array data 
from this study are available from the Gene Expression 
Omnibus (GEO) repository under accession number 
GSE140124 (https ://www.ncbi.nlm.nih.gov/geo/).
Results
Genomic landscape of pediatric bithalamic gliomas
To investigate the molecular pathogenesis of bithalamic 
gliomas, we performed targeted next-generation sequenc-
ing and genome-wide copy-number analysis on tumor 
samples from 13 children. The ten male and three female 
patients, ages 2–16 years, all had diffuse gliomas involving 
the bilateral thalami at time of initial presentation [Fig. 1a, 
Table 1, and Supplementary Table 1 (Online Supplement 
1)]. Imaging revealed bulky expansion of the bilateral 
thalami that was T2 and FLAIR hyperintense, and either 
lacked enhancement (11 cases) or had minimal enhance-
ment (2 cases) following contrast administration [Supple-
mentary Fig. 1 (Online Supplement 2) and Supplementary 
Table 4 (Online Supplement 1)]. Infiltration into the basal 
ganglia, brainstem, or insular cortex was often seen at time 
of initial imaging. Only one patient (#12) was identified to 
have disseminated disease throughout the ventricular sys-
tem and along the spinal cord at time of presentation. All 
tumors were unresectable, with only a stereotactic biopsy 
(ten cases) or limited subtotal resection (three cases) per-
formed for diagnosis and molecular profiling. Histologic 
diagnosis was diffuse astrocytoma for three tumors, ana-
plastic astrocytoma for nine tumors, and glioblastoma for 
one tumor [Supplementary Fig. 2 (Online Supplement 2) 
and Supplementary Table 5 (Online Supplement 1)]. All 
were diffusely infiltrating astrocytic neoplasms with varia-
ble cellularity and mitotic activity, which uniformly lacked 
both necrosis and microvascular proliferation except for 
patient #6 whose tumor had foci of necrosis.
Eleven tumors (85%) harbored mutations in the EGFR 
oncogene in the absence of accompanying EGFR gene 
amplification [Fig. 1b and Supplementary Table 6 (Online 
Supplement 1)]. Nine of these EGFR mutations were small 
in-frame insertions within exon 20 that encodes a por-
tion of the intracellular tyrosine kinase domain [Fig. 1c 
and Supplementary Figs. 3 and 4 (Online Supplement 2)], 
where mutations are common in lung adenocarcinoma 
[2, 24, 44] and fibrous hamartoma of infancy [26], but 
have not been previously identified in gliomas. The other 
two cases had EGFR mutations (p.A289T or p.A289V) 
located in exon 7 within the extracellular ligand-binding 
domain [Fig. 1c and Supplementary Fig. 5 (Online Sup-
plement 2)]. While two of the bithalamic gliomas harbored 
p.A289T/V that is a mutational hotspot in the extracel-
lular domain recurrently seen in glioblastomas in adults, 
the exon 20 insertions identified in nine of the bithalamic 
gliomas were not seen in any of 326 pediatric high-grade 
and diffuse intrinsic pontine gliomas from a recent meta-
analysis [18], nor the greater than 1,100 adult diffuse glio-
mas studied to date by The Cancer Genome Atlas [10].
Only 2 of the 13 bithalamic gliomas lacked identifiable 
EGFR mutations, one of which harbored focal high-level 
amplification of a wild-type EGFR allele (patient #12). The 
one bithalamic glioma lacking EGFR mutation or ampli-
fication in this cohort (patient #13) was both radiographi-
cally and histologically distinct compared to the other 12 
tumors [Supplementary Fig. 2 (Online Supplement 2) and 
Supplementary Tables 4 and 5 (Online Supplement 1)]. A 
more heterogeneous appearance with both enhancement 
and restricted diffusion was seen on MR imaging, whereas 
higher cell density, calcifications, and more severe pleo-
morphism were seen on histology compared to the other 
12 tumors.
Whereas histone H3 K27M mutation is frequent in diffuse 
gliomas with unilateral involvement of the thalamus at time 
of presentation, we find that bithalamic gliomas in children 
rarely harbor H3 K27M mutation (only 2 of 13 cases, 15%). 
Instead, we find that they often harbor alterations in other 
epigenetic regulatory genes. One tumor harbored focal high-
level amplification of KDM6A, which encodes a lysine dem-
ethylase enzyme with specificity for lysine 27 of histone H3. 
Three tumors harbored homozygous deletions or truncating 
mutations in the BCOR and BCORL1 transcriptional co-
repressor genes (two with dual inactivation of both genes), 
one tumor harbored a truncating mutation in the CREBBP 
histone acetyltransferase gene, and one harbored a truncat-
ing mutation in the LZTR1 transcriptional regulatory gene 
(Fig. 1b). Thus, while bithalamic gliomas in children often 
lack the histone H3 K27M mutation that is frequent in their 
unilateral counterparts, they often harbor alterations in other 
epigenetic regulators. Immunohistochemical staining for his-
tone H3 lysine 27 trimethylation (H3K27me3) revealed loss 
in eight of the nine evaluated tumors [89%, Supplementary 
Fig. 2 (Online Supplement 2) and Supplementary Table 5 
(Online Supplement 1)] despite only one of these harboring 
HIST1H3B p.K27M mutation, indicating alternative mecha-
nisms in bithalamic gliomas of blocking this histone tail 
modification critical for glial cell differentiation.
Additionally, inactivating mutations of the TP53 tumor 
suppressor gene were present in eight cases (62%), and 
 Acta Neuropathologica
1 3
alterations of cell cycle regulators were also frequent (38%). 
Two tumors harbored mutations in CDKN2C, two harbored 
focal high-level amplification of CDK6, one harbored focal 
high-level amplification of CCND2, and one harbored focal 
homozygous deletion of CDKN2A/B [Fig. 1b, Supplemen-
tary Fig. 6 (Online Supplement 2), and Supplementary 
Table 7 (Online Supplement 1)]. Only two cases harbored 
hotspot mutations in the promoter region of the TERT gene, 
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and none of the other cases were found to harbor alterations 
associated with telomere maintenance (e.g., ATRX mutation/
deletion or TERT amplification or promoter rearrangement). 
Except for one tumor that harbored focal PDGFRA ampli-
fication in addition to EGFR exon 20 insertion (patient #6), 
this cohort of bithalamic gliomas lacked fusions, amplifi-
cations, or mutations in the other receptor tyrosine kinase 
genes known to be common in pediatric gliomas (e.g., MET, 
FGFR1, ALK, ROS1, and NTRK1-3). Notably, mutations or 
rearrangements involving BRAF, RAF1, MYB, and MYBL1 
that are common in pediatric low-grade gliomas were also 
not seen in any of the tumors. Additionally, mutations in 
components of the PI3-kinase pathway (PIK3CA, PIK3R1, 
and PTEN) that are common in both pediatric and adult glio-
mas were absent in this cohort of bithalamic gliomas. The 
somatic mutation burden was very low in each of the tumors 
(less than 3 somatic mutations per Mb). Two of the tumors 
(#5 and #8) demonstrated flat copy-number profiles, while 
the other cases demonstrated several chromosomal gains and 
losses. Recurrent cytogenetic alterations included trisomy 
1q present in seven tumors (54%), trisomy 7 in six tumors 
(46%), trisomy 5 or 5p in four tumors (31%), and monosomy 
17p in four tumors [31%, Supplementary Table 7 (Online 
Supplement 1) and representative genome-wide copy-num-
ber plots shown in Supplementary Fig. 6 (Online Supple-
ment 2)]. Four of the six tumors with trisomy 7 were those 
harboring EGFR mutations that was likely resulting in extra 
copies of the mutant allele in tumor cells.
Multi‑region sequencing of bithalamic gliomas 
confirms clonality of EGFR mutations
The variant allele frequency for the EGFR mutations iden-
tified in the 11 bithalamic gliomas ranged from 17 to 61% 
[Supplementary Table 6 (Online Supplement 1)]. Cases with 
the highest EGFR variant allele frequencies had genomic 
DNA isolated from areas histologically visualized to con-
tain a high tumor cell content (and included those harbor-
ing trisomy 7), whereas cases with the lowest mutant allele 
frequencies had genomic DNA that was isolated from tumors 
containing more sparse infiltrating tumor nuclei. Therefore, 
these data suggest that EGFR mutation is a clonal heterozy-
gous alteration in bithalamic gliomas, indicating that it is 
probably an early or initiating event in tumorigenesis. To 
further assess this hypothesis, we performed multi-region 
sequencing analysis on two of the bithalamic gliomas har-
boring EGFR mutations.
Sequencing of a stereotactic biopsy at time of initial pres-
entation for patient #10 revealed EGFR p.A289T mutation, 
CDKN2C p.D95del mutation, and gains of chromosomes 
1q, 5, 7, and distal Xq. This child was treated with 59 Gy of 
intensity-modulated radiation therapy, followed by a com-
bination of temozolomide plus afatinib, a small-molecule 
kinase inhibitor with specificity for EGFR. Surveillance 
imaging revealed slow disease progression over the course 
of 14 months, with increasing disease burden extending into 
the bilateral basal ganglia and insular cortices (Fig. 2a). 
A repeat stereotactic biopsy from the right temporal lobe 
was then performed for clinical trial eligibility purposes. 
Sequencing analysis performed on this biopsy revealed the 
identical EGFR p.A289T mutation and gains of chromo-
somes 1q, 5, and 7; however, the CDKN2C mutation and 
gain of distal chromosome Xq seen in the initial biopsy from 
the right thalamus were not present.
Brain imaging at time of initial presentation for patient #7 
revealed substantial involvement of the bilateral thalami, but 
was asymmetric with more bulky disease burden in the left 
thalamus. This child underwent a limited subtotal resection 
from the posterior aspect of the left thalamus, and sequenc-
ing analysis was performed on four independent areas of 
tumor from this resection specimen (Fig. 2b). The identi-
cal EGFR p.A767delinsASVD insertion within exon 20 
was present in each of the four tumor regions, as was focal 
homozygous deletion of BCOR and a truncating nonsense 
mutation in BCORL1. Together, the findings from multi-
region sequencing of these two patients further support that 
EGFR mutation is a clonal alteration in bithalamic gliomas, 
thereby indicating that it is likely an early or initiating event 
in tumorigenesis.
Epigenomic analysis reveals that bithalamic gliomas 
are a distinct glioma entity
We next studied the genome-wide DNA methylation pro-
files from 10 of the 13 bithalamic gliomas using Infinium 
Methylation 850k or 450k BeadChip arrays (Illumina). 
Analysis of DNA methylation profiles was performed by 
t-SNE plotting [Fig. 3 and Supplementary Fig. 7 (Online 
Supplement 2)] and unsupervised hierarchical clustering 
[Supplementary Fig. 8 (Online Supplement 2)] against 
616 glioma reference samples or 2,801 reference sam-
ples spanning 82 CNS tumor entities and 9 control tissues 
Fig. 1  Genetic landscape of pediatric bithalamic gliomas. a Axial 
T2-weighted fluid-attenuated inversion recovery (FLAIR) MR image 
from an 11-year-old girl (patient #3) showing an expansile mass 
involving the bilateral thalami (top). Histology from the stereotac-
tic biopsy revealing a diffuse astrocytic neoplasm with pleomorphic 
nuclei and occasional mitotic figures (H&E stain, × 400 magnifica-
tion, middle). Negative immunohistochemical stain for histone H3 
K27M-mutant protein (× 400 magnification, bottom). b Oncoprint 
table of the clinical features and likely pathogenic alterations identi-
fied in biopsies from 13 children with bithalamic gliomas. Exon num-
ber where the EGFR mutations are located is annotated. c Diagram of 
human EGFR protein with the location of the recurrent exon 20 small 
in-frame insertions within the intracellular tyrosine kinase domain 
and p.A289T/V missense mutations within the extracellular ligand-
binding domain. UniProt P00533, RefSeq NM_005228
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[Supplementary Tables 8 and 9 (Online Supplement 1)]. 
Additionally, random forest classification using the DKFZ 
MolecularNeuropathology.org online classifier tool (ver-
sion 11b4) was performed [Supplementary Table  10 
Online Supplement 1)]. This analysis demonstrated that 
bithalamic gliomas harbor DNA methylation patterns 
distinct from all glioma and other brain tumor entities 
that have been studied to date, albeit with some limited 
overlap with the “RTK III subclass” of the methylation 
class “Glioblastoma, IDH-wildtype”, which is a poorly 
characterized subgroup of IDH-wild-type glioblastomas 
in the cerebral hemispheres of children [9]. Notably, the 
bithalamic gliomas were entirely distinct from their unilat-
eral counterparts belonging to the methylation class “Dif-
fuse midline glioma, H3 K27M-mutant”, and were also 
distinct from the "Glioblastoma, IDH-wildtype, midline 
subclass" that is comprised of glioblastomas located in 
midline structures lacking H3 K27M mutation but fre-
quently harboring FGFR1 mutations [9]. Unfortunately, 
no remaining tumor tissue was available for methylation 
analysis from the two bithalamic gliomas in this cohort 
which harbored histone H3 K27M mutations (patient #11 
with dual EGFR p.A289T and HIST1H3B p.K27M muta-
tions and patient #12 with dual EGFR amplification and 
H3F3A p.K27M mutation).
EGFR exon 20 kinase domain insertion transforms 
human astrocytes
As EGFR exon 20 small in-frame insertions have not been 
previously identified in gliomas, we examined the effects 
of introducing one of these insertion mutations in primary 
human astrocytes. Lentiviral transduction of SVG-p12 cells, 
an immortalized fetal astrocyte cell line, with empty vector, 
EGFR wild-type, EGFR p.A289T mutation located within 
exon 7 in the extracellular ligand-binding domain, and 
EGFR p.A767delinsASVG mutation located within exon 20 
in the intracellular tyrosine kinase domain was performed. 
Similar levels of ectopic overexpression were observed for 
the wild-type and mutant EGFR isoforms (Fig. 4a). The exon 
20 insertion mutant resulted in increased phosphorylation of 
ERK1/2 and Akt, similar to the p.A289T mutation (Fig. 4a). 
Both the exon 20 insertion mutation and the p.A289T extra-
cellular domain mutation conferred anchorage-independent 
colony formation in soft agar to a similar extent (Fig. 4b). 
In contrast, SVG-p12 cells transduced with empty vector or 
wild-type EGFR did not yield appreciable colony forma-
tion (Fig. 4b). These data indicate that the exon 20 insertion 
mutations present in pediatric bithalamic gliomas are onco-
genic alterations, equivalent in tumorigenic capacity to the 
extracellular domain mutations in EGFR that are known to 
be common in glioblastomas in adults.Ta
bl
e 
1 
 (c
on
tin
ue
d)
Pa
tie
nt
Ag
e  
(y
ea
rs)
Se
x
Su
rg
ica
l  
pr
oc
ed
ur
e
Hi
sto
lo
gy
Ge
ne
tic
  
alt
er
ati
on
s
Ra
di
ati
on
 th
er
ap
y
In
iti
al 
 
ch
em
ot
he
ra
py
Ad
di
tio
na
l 
ra
di
ati
on
Ad
di
tio
na
l 
ch
em
ot
he
ra
py
Ou
tco
m
e
Fo
llo
w-
up
 
(m
on
th
s)
#1
2
7
M
Bi
op
sy
An
ap
las
tic
  
as
tro
cy
to
m
a
EG
FR
 am
p, 
TP
53
 m
is,
 N
F1
 
no
n +
 fs
, H
3F
3A
 
K2
7M
Cr
an
io
sp
in
al 
36
 G
y +
 4 
Gy
 
Th
ala
m
ic 
bo
os
t
Te
m
oz
ol
om
id
e, 
be
va
ciz
um
ab
, 
ce
tu
xi
m
ab
No
ne
No
ne
Di
ed
 of
 di
se
as
e
2
#1
3
9
M
ST
R
An
ap
las
tic
  
as
tro
cy
to
m
a
TP
53
 m
is,
 
CD
KN
2C
 
in
de
l, 
BC
OR
 fs
, 
BC
OR
L1
 no
n, 
LZ
TR
1 f
s
Lo
ca
liz
ed
 59
 G
y
Be
va
ciz
um
ab
No
ne
No
ne
Di
ed
 of
 di
se
as
e
13
ST
R 
su
bt
ot
al 
re
se
cti
on
, i
ns
 sm
all
 in
-fr
am
e i
ns
er
tio
n, 
fs 
fra
m
es
hi
ft 
m
ut
ati
on
, d
el
 h
om
oz
yg
ou
s d
ele
tio
n, 
m
is
 m
iss
en
se
 m
ut
ati
on
, a
m
p 
fo
ca
l a
m
pl
ifi
ca
tio
n, 
in
de
l s
m
all
 in
-fr
am
e i
ns
er
tio
n 
or
 d
ele
tio
n, 
no
n n
on
se
ns
e m
ut
ati
on
EG
FR
 an
d M
EK
 sm
all
-m
ol
ec
ul
e t
yr
os
in
e k
in
as
e i
nh
ib
ito
rs 
ar
e i
n b
ol
d
 Acta Neuropathologica
1 3
Targeted inhibition of mutant EGFR depends 
on mutation location in the extracellular domain 
versus intracellular kinase domain
To guide the precision treatment of children with bitha-
lamic gliomas, we investigated the efficacy of a panel of 
small-molecule tyrosine kinase inhibitors in two isogenic 
human astrocyte models, SVG-p12 cells, and normal human 
astrocytes immortalized with ectopic expression of TERT 
and HPV E6 and E7 proteins (iNHAs) that have been pre-
viously described [37]. Following lentiviral transduction 
with empty vector, wild-type EGFR, p.A289T mutant, and 
p.A767delinsASVG mutant isoforms, cells were treated with 
the panel of kinase inhibitors. All kinase inhibitors reduced 
viability of the astrocytes expressing mutant EGFR isoforms 
compared to empty vector [Fig. 4c and Supplementary Fig. 9 
(Online Supplement 2)]. However, the relative difference 
in survival between EGFR mutant isoforms, wild-type 
EGFR, and empty vector were variable among the differ-
ent compounds tested. Gefitinib indiscriminately reduced 
survival of cells overexpressing either wild-type or mutant 
EGFR isoforms in comparison to empty vector. In contrast, 
afatinib only reduced survival of astrocytes overexpressing 
mutant EGFR isoforms but not wild type. Erlotinib reduced 
survival of astrocytes expressing p.A289T extracellular 
domain mutation to a greater extent than those express-
ing p.A767delinsASVG exon 20 kinase domain mutation, 
whereas poziotinib reduced survival of astrocytes expressing 
p.A767delinsASVG exon 20 kinase domain mutation to a 
greater extent than those expressing p.A289T extracellular 
domain mutation. To ascertain which kinase inhibitor pro-
duced the greatest survival reduction in astrocytes overex-
pressing wild-type and mutant EGFR isoforms, we next 
compared the relative survival data across the different 
compounds (Fig. 4d). For astrocytes overexpressing wild-
type EGFR, gefitinib produced the greatest reduction in rela-
tive survival among the tested inhibitors. For the p.A289T 
extracellular domain mutation, erlotinib, gefitinib, lapatinib, 
afatinib, and neratinib produced comparable reductions in 
relative survival. For the p.A767delinsASVG intracellu-
lar kinase domain mutation, gefitinib, lapatinib, afatinib, 
and neratinib produced comparable reductions in relative 
survival. Together, these data provide the foundation for a 
genomically guided treatment approach using specific kinase 
inhibitors dependent on the precise EGFR alteration present 
in a patient’s glioma.
Treatment of children with bithalamic gliomas 
harboring EGFR exon 20 insertion with kinase 
inhibitors
The treatment regimens and clinical outcomes for the 13 
children with bithalamic gliomas in this study cohort are 
shown in Table 1 [with more extensive clinical data includ-
ing radiation method and chemotherapy dosage listed in 
Supplementary Table 1 (Online Supplement 1)]. As there 
are no known effective treatments for bithalamic gliomas, 
four children in this study cohort were treated with EGFR 
or MEK small-molecule kinase inhibitors. Patient #1 is an 
11-year-old boy who was treated with intensity-modulated 
Fig. 2  Multi-region sequencing of pediatric bithalamic gliomas 
reveals that EGFR mutations are clonal and likely an early or initiat-
ing event during tumorigenesis. a Sequencing of a stereotactic biopsy 
from the right thalamus at time of initial presentation for patient #10 
revealed EGFR p.A289T mutation, CDKN2C p.D95del mutation, and 
gains of chromosomes 1q, 5, 7, and distal Xq. At 14 months follow-
ing radiation and chemotherapy, a repeat stereotactic biopsy from 
the right temporal lobe was performed with sequencing analysis 
revealing the identical EGFR p.A289T mutation and gains of chro-
mosomes 1q, 5, and 7. b Imaging at time of initial presentation for 
patient #7 revealed substantial involvement of the bilateral thalami 
but with more bulky disease burden in the left thalamus. A limited 
subtotal resection from the posterior aspect of the left thalamus was 
performed, with sequencing analysis performed on four independ-
ent areas of tumor from this resection specimen. The identical EGFR 
p.A767delinsASVD insertion within exon 20, focal homozygous 
deletion of BCOR, and nonsense mutation in BCORL1 was present in 
each of the four tumor regions
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radiation therapy and then with a combination of osimer-
tinib, temozolomide, and bevacizumab given the finding 
of EGFR exon 20 insertion. Slow tumor growth over the 
following 12 months was seen on follow-up imaging, at 
which point this child was treated with an additional course 
of radiation therapy and then started on a combination of 
afatinib and bevacizumab (Fig. 5a). Continued slow tumor 
progression was observed, and he succumbed to disease 
at 22 months after the initial diagnosis. Patient #3 is an 
11-year-old girl who was treated with intensity-modulated 
Fig. 3  Epigenomic analysis reveals that pediatric bithalamic glio-
mas are a distinct glioma entity. Genome-wide DNA methylation 
profiles from ten bithalamic gliomas were clustered together with 
616 glioma reference samples [Supplementary Table 9 (Online Sup-
plement 1)] by t-SNE analysis. Bithalamic gliomas (BITHAL) form 
a cluster that is distinct from all glioma entities that have been stud-
ied to date, albeit with some limited overlap with the “Glioblastoma, 
IDH-wildtype, RTK III subclass”, which is a poorly characterized 
subgroup of glioblastomas in the cerebral hemispheres of children 
[9]. The bithalamic gliomas are entirely distinct from their unilateral 
thalamic counterparts belonging to the methylation class “Diffuse 
midline glioma, H3 K27M-mutant” (DMG-K27), and are also distinct 
from the "Glioblastoma, IDH-wildtype, midline subclass" (GBM-
MID) that is comprised of glioblastomas located in midline structures 
lacking H3 K27M mutation [9]. A-IDH, IDH-mutant astrocytoma. 
CONTR-HEMI, normal cerebral hemisphere. GBM-G34, diffuse 
hemispheric glioma with H3 G34 mutation. IHG infantile hemi-
spheric glioma, PXA pleomorphic xanthoastrocytoma
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radiation therapy followed by temozolomide and then lomus-
tine (CCNU) for progressive disease. A second biopsy was 
performed for molecular profiling purposes at 9 months after 
the initial diagnosis revealing EGFR exon 20 insertion and 
CDK6 amplification, for which therapy was transitioned to 
the MEK inhibitor trametinib in combination with ribociclib 
Fig. 4  EGFR mutations in pediatric bithalamic gliomas are oncogenic 
and confer sensitivity to specific tyrosine kinase inhibitors. a Western 
blots on total cell lysate from SVG-p12 immortalized human astro-
cytes after lentiviral transduction with empty vector, EGFR wild-
type, or EGFR mutant isoforms. b Colony formation in soft agar of 
SVG-p12 immortalized human astrocytes after lentiviral transduc-
tion with empty vector, EGFR wild-type, or EGFR mutant isoforms. 
Images of representative wells (left) and quantitation of colony num-
ber per well (right) are shown. Error bars represent standard error 
from the mean of 12 replicates from two independent experiments. 
c Survival plots of SVG-p12 immortalized human astrocytes trans-
duced with empty vector, EGFR wild-type, and EGFR mutant iso-
forms followed by treatment with various tyrosine kinase inhibitors 
at the indicated doses for 96 h. Each data point is the mean of nine 
replicates from three independent experiments, and error bars show 
standard error of the mean. d Comparison of kinase inhibitor efficacy 
in SVG-p12 immortalized human astrocytes expressing EGFR wild-
type or mutant isoforms
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Fig. 5  Small-molecule tyrosine kinase inhibition may extend sur-
vival for children with bithalamic gliomas. a Imaging showing dis-
ease course for patient #1 whose therapy included both osimertinib 
and afatinib. Images are from axial T2/FLAIR sequences taken at dif-
ferent stages during treatment. b Kaplan–Meier survival analysis of 
41 children with bithalamic gliomas, including the 13 children from 
this study combined with all historical cases of biopsy-proven bitha-
lamic diffuse gliomas reported in the literature [see Supplementary 
Table 11 (Online Supplement 1)]. c Kaplan–Meier survival analysis 
of these 41 children with bithalamic gliomas stratified based on his-
tologic classification as diffuse astrocytoma, anaplastic astrocytoma, 
or glioblastoma. d Kaplan–Meier survival analysis of the 11 children 
with bithalamic gliomas harboring EGFR mutations from this study 
cohort stratified by those whose therapy included a small-molecule 
EGFR or MEK kinase inhibitor (n = 4) versus those children whose 
treatment did not include a small-molecule tyrosine kinase inhibitor 
(n = 7). p value was calculated by log-rank (Mantel–Cox) test
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(a CDK4/6 small-molecule inhibitor). Slow tumor progres-
sion was observed over the next several months, and she 
succumbed to disease at 21 months from the initial diag-
nosis. Patient #5 is a 3-year-old boy who was treated with 
intensity-modulated proton therapy with concurrent osi-
mertinib and temozolomide, and then was continued on 
osimertinib and temozolomide given the finding of EGFR 
exon 20 insertion. Slow tumor progression was observed 
on follow-up imaging over the next several months. This 
child is currently alive with progressive disease at 8 months 
since diagnosis. Patient #10 is a 5-year-old boy who was 
treated with intensity-modulated radiation therapy, and then 
with a combination of afatinib and temozolomide given the 
finding of EGFR p.A289T missense mutation. Slow tumor 
progression was observed over the next several months. He 
was treated with an additional course of radiation therapy at 
12 months from initial diagnosis and subsequently under-
went an additional biopsy for molecular profiling purposes, 
which demonstrated the identical EGFR p.A289T without 
any additional pathogenic alterations (Fig. 2a). He remains 
alive with slowly progressive disease at 19 months since 
initial diagnosis, currently on a combination of osimertinib, 
CCNU, and bevacizumab. No significant toxicities associ-
ated with the osimertinib, afatinib, or trametinib were expe-
rienced by the four children in this cohort.
Given that pediatric bithalamic diffuse gliomas appear to 
represent a distinct tumor entity based on their unique ana-
tomic location, genetic signature, and epigenomic landscape, 
we sought to define the clinical outcomes for affected chil-
dren. To do this, we collated clinical data from all children 
with biopsy-proven diffuse gliomas of the bilateral thalami 
reported in the published literature, including patient age, 
sex, diagnostic surgical procedure, histologic diagnosis, 
radiation treatment, chemotherapy, and survival [Supple-
mentary Table 11 (Online Supplement 1)]. Tumors with 
a diagnosis of pilocytic astrocytoma or those identified to 
harbor KIAA1549-BRAF fusion (the defining genetic altera-
tion of pilocytic astrocytoma) were excluded, as these do 
not represent true bithalamic diffuse gliomas. Kaplan–Meier 
survival analysis was performed on this historical cohort of 
pediatric bithalamic gliomas, our study cohort of pediatric 
bithalamic gliomas, and these two cohorts combined (com-
bined cohorts shown in Fig. 5b). The median survival was 
7 months for the historical cohort, 14 months for our study 
cohort, and 10 months for the combined study cohort. Nearly 
all children from both cohorts succumbed to disease within 
2 years, with only a few children in the historical cohort hav-
ing longer survival, which may potentially represent inclu-
sion of other tumor types (especially given the absence of 
detailed molecular characterization in these few tumors from 
children with long-term survival). Kaplan–Meier survival 
analysis of the separate and combined study cohorts with 
stratification based on histologic classification as diffuse 
astrocytoma vs. anaplastic astrocytoma vs. glioblastoma did 
not reveal any appreciable differences, thus indicating that 
histologic grading is not a robust predictor of differential 
survival in pediatric bithalamic gliomas (Fig. 5c). This is not 
unexpected given that only small stereotactic biopsies are 
typically performed in affected children that may preclude 
accurate histologic grading. Overall, this analysis demon-
strates that survival for children with bithalamic gliomas is 
poor irrespective of histologic grade, with outcomes simi-
lar to other diffuse glioma entities with grade IV designa-
tions in the 2016 World Health Organization Classification 
of Tumors of the Central Nervous System such as “diffuse 
midline glioma, H3 K27M-mutant” and “glioblastoma, 
IDH-wildtype”.
To evaluate the potential survival benefit conferred by 
EGFR and MEK kinase inhibitor therapy, we examined 
clinical outcomes for the eleven children in our study 
cohort whose bithalamic gliomas harbored EGFR muta-
tion (patients #1–11). We performed Kaplan–Meier sur-
vival analysis stratified by those children whose treatment 
included a small-molecule EGFR or MEK kinase inhibi-
tor (n = 4) versus those whose treatment did not include a 
small-molecule kinase inhibitor (n = 7; Fig. 5d). Median 
survival was 21.5 months for those children whose treat-
ment included a kinase inhibitor versus 13 months for those 
children whose treatment did not include a kinase inhibitor 
(p = 0.010 by log-rank test). While the patient numbers are 
small, this analysis does suggest a potential survival benefit 
from the addition of a small-molecule tyrosine kinase inhibi-
tor to the treatment regimen for children with bithalamic 
gliomas harboring EGFR mutation.
Discussion
Brain tumors are the most common solid tumors of child-
hood. While outcomes are good for some low-grade sub-
types such as pilocytic astrocytoma, other subtypes such as 
diffuse intrinsic pontine glioma and bithalamic glioma are 
unresectable tumors and have a uniformly poor prognosis. 
Genomically tailored therapy has the potential to improve 
outcomes for these malignant childhood brain tumors.
We have identified that bithalamic gliomas represent a 
distinct molecular entity characterized by frequent EGFR 
and TP53 mutations in the absence of EGFR gene ampli-
fication and only rare histone H3 p.K27M mutation. This 
is in contrast to their unilateral thalamic counterparts that 
lack EGFR mutation, have a high frequency of H3F3A or 
HIST1H3B p.K27M mutation, along with recurrent accom-
panying alterations in ATRX, FGFR1, PIK3CA, and ACVR1 
that were not present in our cohort of bithalamic gliomas 
[18, 36, 42, 43]. The EGFR mutations in bithalamic gliomas 
are most commonly small in-frame insertions within exon 
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20 in the intracellular tyrosine kinase domain, unlike the 
missense mutations and intragenic deletions involving exons 
encoding the extracellular domain that are often present on 
the amplified EGFR allele in glioblastomas in adults [5, 16, 
41]. Apart from bithalamic gliomas, EGFR mutations or 
amplifications are otherwise rare in pediatric gliomas, being 
found in less than 4% of pediatric high-grade and diffuse 
brainstem gliomas according to the largest meta-analysis 
to date [18]. Notably, while the bithalamic gliomas in this 
cohort share a similar epigenome that is largely distinct from 
all other glioma subtypes that have been studied to date, 
we did observe some overlap with the RTK III methyla-
tion subclass of IDH-wild-type glioblastomas. This RTK 
III methylation subclass is a poorly characterized group of 
glioblastomas in the cerebral hemispheres of children which 
have been identified to harbor frequent EGFR amplification 
in the small number of cases studied to date [9].
Studies have shown that glioblastoma cells from adults 
harboring EGFR activation via amplification accompa-
nied by intragenic deletion of exons 2–7 (EGFRvIII vari-
ant) are inhibited by erlotinib [34]. Unfortunately, clini-
cal trials examining the efficacy of erlotinib in adults with 
glioblastoma produced largely unsuccessful results [7, 27, 
29]. Subsequent investigation suggested potential explana-
tions for the failure of erlotinib in adult glioblastoma. One 
study found that erlotinib was less efficacious for extracel-
lular domain mutations in adult glioblastomas compared 
with the kinase domain mutations in lung cancers [40]. 
Other studies have reported that inactivation of the PTEN 
tumor suppressor gene, de-repression of PDGFRB expres-
sion, and dynamic regulation of extrachromosomal mutant 
EGFR amplicons are also potential resistance mechanisms 
of glioblastoma to erlotinib [1, 19, 21]. Among EGFR kinase 
domain mutations in lung cancer, exon 20 insertions have 
been correlated with worse outcomes and relative resist-
ance to erlotinib [2, 24, 44]. Poziotinib has been identified 
as a compound with enhanced efficacy in lung carcinomas 
harboring exon 20 insertions relative to other more com-
mon kinase domain mutations (e.g., p.T790M), thought to 
be attributable to poziotinib’s smaller size and increased 
flexibility compared to other large, rigid inhibitors [14, 32, 
33]. However, the sensitivity of different EGFR mutations 
to the currently available armamentarium of EGFR kinase 
inhibitors had not been examined in isogenic glioma model 
systems.
Given the frequent EGFR mutation in bithalamic glio-
mas, we speculated that this creates a therapeutic vulner-
ability that can be targeted with small-molecule kinase 
inhibitors in children affected with this disease. We, there-
fore, tested a panel of kinase inhibitors in two isogenic 
astrocyte cell cultures modeling exon 20 kinase domain 
mutation (specific to pediatric bithalamic glioma), exon 
7 extracellular domain mutation (seen in both pediatric 
bithalamic glioma and adult glioblastoma), and amplifica-
tion of wild-type EGFR (specific to adult glioblastoma). 
We found that these mutant EGFR isoforms or overex-
pression of wild-type EGFR cause sensitivity to kinase 
inhibitor treatment. However, the relative efficacy of the 
different compounds tested was variable dependent on 
location of the EGFR mutation versus overexpression of 
wild-type EGFR. For example, gefitinib indiscriminately 
killed astrocytes overexpressing either wild-type or mutant 
EGFR isoforms. In contrast, afatinib killed astrocytes 
expressing mutant EGFR isoforms but not overexpress-
ing wild-type EGFR. This indicates that for glioblasto-
mas in adults harboring amplification of a wild-type EGFR 
allele, gefitinib is more likely than afatinib to be effica-
cious. We also observed differential drug sensitivity based 
on location of the EGFR mutation, with erlotinib being 
more efficacious for astrocytes expressing extracellular 
domain mutation and poziotinib being more efficacious 
for astrocytes expressing exon 20 kinase domain mutation. 
Among the tested inhibitors, afatinib had the widest thera-
peutic window between astrocytes expressing either of the 
mutant isoforms versus astrocytes with wild-type EGFR 
expression. Together, these data provide the preclinical 
rationale for an individualized treatment strategy using 
kinase inhibitors targeting the specific EGFR alteration 
present in a patient’s glioma. Additionally, as EGFR muta-
tion results in downstream activation of the MAP kinase 
signaling pathway, MEK inhibition represents another 
potential therapeutic option. Notably, blood–brain barrier 
penetration represents an important consideration when 
selecting small-molecule tyrosine kinase inhibitors for use 
in glioma patients.
In summary, we have identified that bithalamic gliomas in 
children represent a molecularly distinct brain tumor entity 
characterized by frequent EGFR mutations and rare histone 
H3 mutations. These EGFR mutations confer selective vul-
nerability to EGFR kinase inhibitors. Our initial experience 
with treatment of four children with bithalamic gliomas har-
boring EGFR mutations with targeted small-molecule kinase 
inhibitors has shown promising survival benefit for this 
lethal pediatric brain tumor. Further evaluation of targeted 
kinase inhibition in a randomized clinical trial setting for 
children with bithalamic gliomas appears warranted based 
on this initial study.
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